Search

• GSK’s meningitis B vaccine Bexsero receives Breakthrough Therapy Designation from US FDA for prevention of Invasive Meningococcal Disease in children 2-10 years of age

  Media

  GlaxoSmithKline plc announced that it has received Breakthrough Therapy Designation from the U.S. FDA for its meningitis B vaccine Bexsero

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-meningitis-b-vaccine-bexsero-receives-breakthrough-therapy-designation-from-us-fda-for-prevention-of-invasive-meningococcal-disease-in-children-2-10-years-of-age/

  First published: 07 February 2018

• GSK receives US approval of Arnuity Ellipta for use in children from 5 years old who suffer from asthma

  Media

  GSK today announced it has received approval from the US Food and Drug Administration (FDA) for the use of Arnuity Ellipta

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-us-approval-of-arnuity-ellipta-for-use-in-children-from-5-years-old-who-suffer-from-asthma/

  First published: 21 May 2018

• GSK and Adaptimmune complete transition of NY-ESO SPEAR T-cell therapy programme to GSK

  Media

  GlaxoSmithKline plc and Adaptimmune Therapeutics plc, announced the transition of the development programme for GSK3377794 to GSK.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-adaptimmune-complete-transition-of-ny-eso-spear-t-cell-therapy-programme-to-gsk/

  First published: 24 July 2018

• Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer

  Media

  TESARO announced the presentation of data from the Phase 1/2 GARNET study

  https://www.gsk.com/en-gb/media/press-releases/data-from-garnet-study-indicates-robust-activity-of-dostarlimab-in-patients-with-advanced-or-recurrent-endometrial-cancer/

  First published: 19 March 2019

• GSK licenses tuberculosis vaccine candidate to the Bill & Melinda Gates Medical Research Institute for continued development

  Media

  GSK announced that it has licensed its M72/AS01E3 tuberculosis disease (TB) vaccine.

  https://www.gsk.com/en-gb/media/press-releases/gsk-licenses-tuberculosis-vaccine-candidate-to-the-bill-melinda-gates-medical-research-institute-for-continued-development/

  First published: 27 January 2020

• Update - GSK Consumer Healthcare

  Media

  GlaxoSmithKline (GSK) plc today confirms it has received three unsolicited, conditional and non-binding proposals from Unilever plc

  https://www.gsk.com/en-gb/media/press-releases/update-gsk-consumer-healthcare/

  First published: 15 January 2022

• China approves Cervarix two-dose vaccine schedule for girls aged 9 to 14 against certain types of cancer-causing human papillomavirus

  Media

  China’s National Medical Products Administration has approved a two-dose vaccine schedule for Cervarix in girls aged between 9 to 14 years.

  https://www.gsk.com/en-gb/media/press-releases/china-approves-cervarix-two-dose-vaccine-schedule-for-girls-aged-9-to-14-against-certain-types-of-cancer-causing-human-papillomavirus/

  First published: 27 May 2022

• Jemperli (dostarlimab) RUBY phase III trial met its primary endpoint in a planned interim analysis in patients with primary advanced or recurrent endometrial cancer

  Media

  Regulatory submissions based on the trial results are planned for the first half of 2023.

  https://www.gsk.com/en-gb/media/press-releases/jemperli-dostarlimab-ruby-phase-iii-trial-met-its-primary-endpoint-in-a-planned-interim-analysis-in-patients-with-primary-advanced-or-recurrent-endometrial-cancer/

  First published: 02 December 2022

• GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

  Media

  GSK announces a major conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses

  https://www.gsk.com/en-gb/media/press-releases/gsk-plc-announces-major-three-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders/

  First published: 22 April 2014

• ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection

  Media

  ViiV Healthcare, Pfizer Inc. and Shionogi Limited with Janssen for cabotegravir and rilpivirine for the treatment of HIV-1 infection.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv-1-infection/

  First published: 07 January 2016